mgta-456
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 9, 2018 (NCT03406962)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Burkitt Lymphoma · Phase 2
- Hodgkin Disease · Phase 2
- Leukemia · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, T-Cell · Phase 2
- Metabolic Diseases · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03674411 | Phase 2 | Sep 30, 2018 | University of Minnesota |
| NCT03406962 | Phase 2 | Feb 9, 2018 | Magenta Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Magenta Therapeutics | For profit | 1 | 1 | 1 | 2018 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1